PART I Overview We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is des...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-107146 | EDGAR | 99K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034575 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0000950170-24-029191 | EDGAR | — |
| 2023-03-27 | 2022-12-31 | 0000950170-23-009991 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002519 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-008081 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007395 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004890 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001564590-18-004727 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001564590-17-003229 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269477 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104991 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-068511 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123249 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093865 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055588 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060201 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039761 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019654 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023190 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014737 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007806 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001193125-26-115958 | EDGAR | 29K words |
| 2026-03-16 | 0001193125-26-107152 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269533 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179463 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105053 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140739 | EDGAR | — |
| 2025-05-28 | 0001193125-25-129470 | EDGAR | — |
| 2025-05-13 | 0001193125-25-118805 | EDGAR | — |
| 2025-05-12 | 0001193125-25-117245 | EDGAR | — |
| 2025-03-06 | 0000950170-25-034585 | EDGAR | — |
207 total filings indexed. 175 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001501989 |
| Ticker | CTMX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cytomx.com |
| Listed | 2015-10-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report